Comparative Effectiveness of Switching to Bictegravir From Dolutegravir-, Efavirenz-, or Raltegravir-Based Antiretroviral Therapy Among Individuals With HIV Who are Virologically Suppressed.

Isaac NúñezYanink Caro-VegaConor James MacDonaldJuan Luis Mosqueda-GómezAlicia Piñeirúa-MenéndezAnthony A Matthews

Published in: Open forum infectious diseases (2024)

Our findings suggest that switching to bictegravir could be more effective in maintaining viral suppression than continuing with dolutegravir, efavirenz, or raltegravir.

Keyphrases

antiretroviral therapy
hiv infected patients
hiv infected
hiv positive
human immunodeficiency virus
hiv aids
sars cov
medical education
south africa